Allergen immunotherapy

Many allergy specialists would suggest that we have come a long way over the past 107 years since the initial publications from the Laboratory of the Department for Therapeutic Inoculations of Saint Mary's Hospital1,2 described the efficacy of subcutaneous allergen immunotherapy (AIT) in pollen allergy. Currently, there is a robust literature showing that AIT has efficacy in the treatment of asthma, prevents the development of further sensitization in mono-sensitized patients, decreases the progression to asthma in those undergoing subcutaneous AIT for allergic rhinitis, and provides persistent therapeutic effect even years after a 3- to 5-year course.

https://ift.tt/2CQikbE